This is the ninth edition of Fast Facts: Prostate Cancer since 1996, testament to the rapid changes in the field and the steadily improving outlook for patients. This new edition provides many key updates:- the Gleason grade grouping- nomograms to evaluate risk- advances in imaging techniques, particularly multiparametric MRI
A summary of the highlights of the Second International Forum on Prostate Cancer, held in Cambridge in 1998. The contributors include scientists, epidemiologists and clinicians who provide both a North American and a European view of treatment. The patient's perspective is also considered.
This text reflects recent advances in the field of prostate cancer, with an emphasis on the latest pharmacotherapeutic options. Topics covered include: investigations; screening; clinical presentation; diagnosis and differential diagnosis; pathology; treatment; and future developments.
Despite potentially curative treatment, many patients with early prostate cancer experience prostate-specific antigen (PSA) progression. Peter Carroll describes potential reasons for PSA progression, how prognosis can be predicted from the rate and timing of rising PSA level and treatment options available.